The Global Hemophilia Drugs Market covered the value of US$ 9875.4 Mn in the year 2017 and is anticipated to reach US$ 15830.3 Mn by 2025.
The Global Hemophilia Drugs Market covered the value of US$ 9875.4 Mn in the year 2017 and is anticipated to reach US$ 15830.3 Mn by 2025. Furthermore, the global market for hemodialysis is expected to report a CAGR of 6.0% during the forecast period. The above information was published in a report, titled “Hemophilia Drugs Market Size”, Share and Global Trend by Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025.”
The report covers:
- Global Hemophilia Drugs Market trends, with detailed analysis on consumer trends & manufacturer trends.
- Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
- Key areas of investments identifying market opportunities and challenges in forecast timeframe.
- Competitive analysis of the industry players along with the overview on strategic management.
- Comprehensive company profiles of the major industry players.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hemophilia-drugs-market-100068
Leading Players operating in the Hemophilia Drugs Market are:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Grifols SA
- CSL Behring
- Octapharma AG
- Pfizer, Inc.
- Bioverativ Inc.
- FERRING LÄKEMEDEL AB
- Aptevo Therapeutics
- Takeda Pharmaceutical Company Limited
- Hoffmann-La Roche Ltd
- Novo Nordisk
The Asia Pacific to Grow at a Rapid Pace with Rising Number of Hemophilia Patients
North America is projected to emerge dominant in the global hemophilia drugs market during the forecast period. This is mainly ascribable to the rising prevalence of hemophilia A and B, especially in countries such as Canada and the U.S. Moreover, in 2017, North America market for hemophilia drugs covered a value of US$ 3,684.7 Mn. Trailing North America, Europe is the second-leading region in the global hemophilia drugs market.
The growth in this region is attributable to the rising healthcare budgets by governments and initiatives by governments to promote hemophilia drugs treatment. On the other hand, the hemophilia drugs market in the Asia Pacific is likely to expand at a higher CAGR between 2017 and 2025 on account of the rising number of patients suffering from hemophilia especially in countries such as China and India.
Pfizer Introduced Gene Therapy to Address Unmet Patient’s Needs
Some of the leading players presently operating in the global market for hemophilia drugs are Grifols SA, Bioverativ Inc., FERRING LÄKEMEDEL AB, Aptevo Therapeutics, Hoffmann-La Roche Ltd, Novo Nordisk, Pfizer, Inc., and CSL Behring. In 2018, companies such as Novo Nordisk, Takeda Pharmaceutical Company Ltd., and F. Hoffmann-La Roche Ltd covered more than half of the share in the global hemodialysis market as per revenue. In 2017, Pfizer, Inc. collaborated with Sangamo Therapeutics, Inc. to commercialize and develop gene therapy programs. The aim was to utilize these programs for Hemophilia A drugs.
Global Hemophilia Treatment Drugs Market Segmentation
By Disease Indication
- Hemophilia A
- Hemophilia B
- Hemophilia C
By Therapy Type
- Recombinant Therapy
- Plasma therapy
- Others
By Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hemophilia-drugs-market-100068
Report Focus:
- Extensive product offerings
- Customer research services
- Robust research methodology
- Comprehensive reports
- Latest technological developments
- Value chain analysis
- Potential Hemophilia Drugs Market opportunities
- Growth dynamics
- Quality assurance
- Post-sales support
- Regular report updates
Reasons to Purchase this Report:
- Comprehensive analysis of the Hemophilia Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
More Trending Topics From Fortune Business Insights@
Mobility Devices Market 2020: Global Share, Growth, Regional Trends, Overview, Demands and Forecast to 2026
Digital PCR Market: 2020 Global Industry Size, Trends, Industry Demand, Future Growth and Forecast Research Report 2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
3844